Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 9.06B 7.86B 7.36B 6.73B 12.71B 863B 12.87B 86.08B 33.78B 431B 34B 33.26B 1,434B P/E 2026 *
-15.2x
P/E 2027 * -29.5x
Enterprise Value 8.66B 7.52B 7.04B 6.44B 12.15B 825B 12.31B 82.32B 32.31B 412B 32.51B 31.81B 1,372B EV / Sales 2026 *
9.41x
EV / Sales 2027 * 6.29x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -
1 day+0.55%
1 week+2.27%
Current month+5.25%
1 month-34.49%
3 months-29.10%
6 months-37.01%
Current year-31.12%
1 week 52.16
Extreme 52.165
55.42
1 month 50
Extreme 50.005
86.74
Current year 50
Extreme 50.005
86.74
1 year 40.37
Extreme 40.37
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap.
31/07/26 Buy

Director

5,000 0.0030%
15/07/26 Free

Director

3,399 0.0021%
15/07/26 Free

Director

3,399 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+0.55%+2.27%+33.91%+37.12% 9.06B
+0.93%-0.63%+3.89%+14.93% 48.7B
+0.26%+2.93%+439.43%+533.80% 42.05B
-1.53%-2.25%+30.95%+7.15% 38.26B
+0.69%+2.40%+10.48%+63.05% 37.5B
+2.47%+2.63%+14.71%+48.37% 31.44B
-0.47%+1.16%+35.93%+126.09% 16.33B
+2.31%-0.49% - - 16.47B
+0.29%+1.87%+8.17%+18.60% 13.98B
-1.43%-2.63%+3.70%-36.38% 12.43B
Average +0.41%+0.91%+64.58%+90.30% 26.62B
Weighted average by Cap. +0.46%+0.98%+87.14%+118.26%

Financials

2026 *2027 *
Net sales 921M 799M 748M 684M 1.29B 87.71B 1.31B 8.75B 3.44B 43.82B 3.46B 3.38B 146B 1.4B 1.22B 1.14B 1.04B 1.97B 134B 1.99B 13.32B 5.23B 66.7B 5.26B 5.15B 222B
Net income -590M -512M -479M -439M -828M -56.2B -839M -5.61B -2.2B -28.08B -2.22B -2.17B -93.46B -319M -277M -259M -237M -447M -30.36B -453M -3.03B -1.19B -15.17B -1.2B -1.17B -50.49B
Net Debt -396M -343M -321M -294M -555M -37.68B -562M -3.76B -1.48B -18.83B -1.49B -1.45B -62.66B -241M -209M -196M -179M -338M -22.93B -342M -2.29B -898M -11.45B -904M -884M -38.13B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
06/08/26 $54.49 +0.55% 2,592,317
05/08/26 $54.19 -1.60% 2,122,267
04/08/26 $55.07 +1.06% 2,688,216
03/08/26 $54.49 +5.25% 3,212,858
31/07/26 $51.77 -2.83% 2,570,536
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
54.49USD
Average target price
89.33USD
Spread / Average Target
+63.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock